Drug intelligence / Profile preview

GLK-10

Development stage: Preclinical
Lead developer: Glykos
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GLK-10 is a preclinical-stage antibody-drug conjugate (ADC) developed by Glykos, designed to target solid tumors expressing the Human Epidermal Growth Factor Receptor 2 (HER2). The asset leverages Glykos's proprietary glycan-mediated site-specific conjugation technology, which aims to produce homogeneous ADCs with improved therapeutic indices compared to conventional stochastic conjugation methods. By specifically binding to HER2, GLK-10 facilitates the targeted delivery of a cytotoxic payload directly into malignant cells, minimizing systemic exposure and potential off-target toxicity.

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on GLK-10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLK-10.

Explore the full profile